A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Adult T-Cell Leukemia-Lymphoma Clinical Trial

Official title:
A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Status Completed

Clinical Trial Summary

To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01724177
Study type	Interventional
Source	Celgene
Contact
Status	Completed
Phase	Phase 2
Start date	November 12, 2012
Completion date	March 21, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01626664` - KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)	Phase 2
Completed	`NCT00920790` - Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma	Phase 2
Completed	`NCT01173887` - Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15	Phase 2
Completed	`NCT01169298` - A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma	Phase 1
Recruiting	`NCT02737046` - Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma	Phase 2